Empagliflozin

Healio and Cardiology Today have compiled a list of the most-read cardiology news of September 2021.

Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic BP or N-terminal pro-B-type natriuretic peptide level, according to two new analyses of results from the EMPEROR-Reduced trial.

Empagliflozin (Jardiance, Boehringer Ingelheim-Eli Lilly) vs. placebo in patients with HFpEF.

Recent data from the EMPEROR-Preserved trial revealed that the SGLT2 inhibitor empagliflozin reduced the risk for serious hospitalizations in patients with heart failure with preserved ejection fraction.

In patients with HF with preserved ejection fraction, empagliflozin reduced risk for serious hospitalizations compared with placebo, according to new data from the EMPEROR-Preserved trial.

The FDA granted breakthrough therapy designation for empagliflozin as an investigational treatment for adults with HF with preserved ejection fraction, Boehringer Ingelheim and Eli Lilly reported.

Healio and Cardiology Today have curated a list of the most-read cardiology news of August 2021.

Recent data showed that flavonoid-rich foods, such as berries, apples, pears and wine, can positively impact BP. It was the top story in cardiology last week.

The SGLT2 inhibitor empagliflozin decreased risk for major renal outcomes in patients with heart failure with reduced ejection fraction but not preserved ejection fraction, according to an analysis of two large randomized controlled trials.

Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor empagliflozin improved clinical outcomes in patients with HF with preserved ejection fraction — the first agent to be shown to do so.